A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS
The objective of the study was to assess the feasibility of using CA -62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy.Material and Methods. A 12-month double-blind clinical trial was conducted by two independent...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2019-11-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1184 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699965122641920 |
|---|---|
| author | G. G. Khakimova Zh. R. Cherkasova S. A. Tsurkan G. A. Fedchikov N. V. Suganov V. A. Gorbunova |
| author_facet | G. G. Khakimova Zh. R. Cherkasova S. A. Tsurkan G. A. Fedchikov N. V. Suganov V. A. Gorbunova |
| author_sort | G. G. Khakimova |
| collection | DOAJ |
| description | The objective of the study was to assess the feasibility of using CA -62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy.Material and Methods. A 12-month double-blind clinical trial was conducted by two independent groups: clinical oncologists and biochemists, and involved 89 patients with different cancers confirmed by histopathological findings. The other inclusion criteria were: the presence of at least one measurable lesion according to the RECIST criteria, ECOG performance status 0-2 and satisfactory laboratory parameters. The expression of CA -62 cancer marker was measured by immunochemiluminescent assay used for the detection of epithelial carcinomas.Results. The elevated level of CA -62 marker was observed in 76 patients before starting the treatment. After completion chemotherapy, the level of this marker decreased to the normal reference ranges (<4600 U/ml) in 53 % of patients and remained increased in 24 % of patients. Of 24 % of patients with the initial low level of CA -62 marker (1000–4000 U/ml) before treatment, 12 % had no changes in the level of this marker during chemotherapy; however, 5 % of these patients had disease progression and 7 % had stable disease after starting the treatment. In 12 % of patients with an initial low CA -62 level, it increased during chemotherapy, indicating disease progression.Conclusion. The changes in the level of CA -62 marker during chemotherapy in patients with gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer showed a high correlation (76–100 % depending on the tumor site) with the performance status of the patients according to RECIST criteria. The CA -62 marker was shown to be feasible for monitoring gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer as well as for assessing the response to chemotherapy. |
| format | Article |
| id | doaj-art-30bc8d90f86449d78b5c46ec4dc6685f |
| institution | DOAJ |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2019-11-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-30bc8d90f86449d78b5c46ec4dc6685f2025-08-20T03:18:26ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682019-11-01185182810.21294/1814-4861-2019-18-5-18-28668A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMASG. G. Khakimova0Zh. R. Cherkasova1S. A. Tsurkan2G. A. Fedchikov3N. V. Suganov4V. A. Gorbunova5N.N. Blokhin National Medical Research Center of OncologyJavis Diagnostics LLC, Skolkovo Innovation CenterJavis Diagnostics LLC, Skolkovo Innovation CenterJavis Diagnostics LLC, Skolkovo Innovation CenterJavis Diagnostics LLC, Skolkovo Innovation CenterN.N. Blokhin National Medical Research Center of OncologyThe objective of the study was to assess the feasibility of using CA -62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy.Material and Methods. A 12-month double-blind clinical trial was conducted by two independent groups: clinical oncologists and biochemists, and involved 89 patients with different cancers confirmed by histopathological findings. The other inclusion criteria were: the presence of at least one measurable lesion according to the RECIST criteria, ECOG performance status 0-2 and satisfactory laboratory parameters. The expression of CA -62 cancer marker was measured by immunochemiluminescent assay used for the detection of epithelial carcinomas.Results. The elevated level of CA -62 marker was observed in 76 patients before starting the treatment. After completion chemotherapy, the level of this marker decreased to the normal reference ranges (<4600 U/ml) in 53 % of patients and remained increased in 24 % of patients. Of 24 % of patients with the initial low level of CA -62 marker (1000–4000 U/ml) before treatment, 12 % had no changes in the level of this marker during chemotherapy; however, 5 % of these patients had disease progression and 7 % had stable disease after starting the treatment. In 12 % of patients with an initial low CA -62 level, it increased during chemotherapy, indicating disease progression.Conclusion. The changes in the level of CA -62 marker during chemotherapy in patients with gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer showed a high correlation (76–100 % depending on the tumor site) with the performance status of the patients according to RECIST criteria. The CA -62 marker was shown to be feasible for monitoring gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer as well as for assessing the response to chemotherapy.https://www.siboncoj.ru/jour/article/view/1184chemotherapygastric cancersmall-cell lung cancercolorectal cancerneuroendocrine cancerovarian cancerса-62 cancer antigenimmunochemiluminescent assaycancer markermonitoringstable diseasedisease progression |
| spellingShingle | G. G. Khakimova Zh. R. Cherkasova S. A. Tsurkan G. A. Fedchikov N. V. Suganov V. A. Gorbunova A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS Сибирский онкологический журнал chemotherapy gastric cancer small-cell lung cancer colorectal cancer neuroendocrine cancer ovarian cancer са-62 cancer antigen immunochemiluminescent assay cancer marker monitoring stable disease disease progression |
| title | A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS |
| title_full | A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS |
| title_fullStr | A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS |
| title_full_unstemmed | A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS |
| title_short | A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS |
| title_sort | pilot clinical trial to monitor response to chemotherapy using the ca 62 marker of epithelial carcinomas |
| topic | chemotherapy gastric cancer small-cell lung cancer colorectal cancer neuroendocrine cancer ovarian cancer са-62 cancer antigen immunochemiluminescent assay cancer marker monitoring stable disease disease progression |
| url | https://www.siboncoj.ru/jour/article/view/1184 |
| work_keys_str_mv | AT ggkhakimova apilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT zhrcherkasova apilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT satsurkan apilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT gafedchikov apilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT nvsuganov apilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT vagorbunova apilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT ggkhakimova pilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT zhrcherkasova pilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT satsurkan pilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT gafedchikov pilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT nvsuganov pilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas AT vagorbunova pilotclinicaltrialtomonitorresponsetochemotherapyusingtheca62markerofepithelialcarcinomas |